What Итразол Treats: Main Uses and Benefits

The medication is applied in addressing infections caused by various fungi. This medication is commonly used to help with conditions presenting with systemic or localized discomfort, and is applied across domains where additional symptomatic support is needed.

Итразол is relevant for easing symptom clusters that may become intense or disruptive, covering infections related to systemic imbalance and those affecting superficial areas like nails and mucosal surfaces. It is generally used in clinical settings that involve acute or unstable symptom patterns, helping to address symptoms that interfere with daily functioning. It provides support that generally helps ease the overall symptom burden.

---

Quick Fact: Support for Disruptive Symptoms

The medication is considered relevant in conditions characterized by periods of heightened symptoms, which supports patients during these episodes. It offers symptomatic relief that helps patients cope more steadily with symptom fluctuations when symptoms create noticeable physiological strain.

Regulatory References

1. NIH MedlinePlus Drug Information on Itraconazole

The eligibility for Итразол (Itraconazole) is formally defined by official regulatory documentation, detailing specific patient groups who must avoid the medicine or who require caution.

Contraindications and Absolute Restrictions

• Congestive Heart Failure ( CHF): The medicine must not be used for the treatment of nail infections (onychomycosis) in patients with a current history or evidence of ventricular dysfunction such as CHF.
• Hypersensitivity: Patients with known allergy or hypersensitivity to Itraconazole or its components are contraindicated.
• Pregnancy: Use is contraindicated during pregnancy for non-life-threatening mycoses. Women of childbearing potential are required to use effective contraception during and for a period after therapy.

Conditional Use and Age-Group Limitations

Population Group	Official Regulatory Status
Pediatric Patients (Children)	Safety and effectiveness are not established. Use is generally not recommended unless benefit outweighs risk.
Organ Impairment	Caution is required for patients with hepatic impairment. Use is not recommended in those with active liver disease or severe renal impairment (oral solution).
Older Adults (Geriatric)	Use requires caution due to the greater frequency of decreased hepatic, renal, or cardiac function in this population.
Lactation (Breastfeeding)	Not recommended as the drug is excreted into breast milk.

Interactions with other medicines and products

Itraconazole's official interaction profile is dominated by two main pharmacological constraints. First, itraconazole is a strong inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme system. Co-administration with medicinal products metabolized by this pathway, such as certain antiarrhythmics, statins, or ergot alkaloids, leads to increased plasma concentrations of the co-administered drug.

Official Interaction Statements

• Contraindicated Combinations: Co-administration with certain CYP3A4-metabolized drugs (e.g., methadone, disopyramide, dronedarone, quinidine, and most ergot alkaloids) is strictly forbidden. This regulatory restriction is due to the potential for the elevated concentrations of these drugs to cause life-threatening adverse reactions, including cardiac dysrhythmias and Torsades de Pointes.
• Use with Caution: For numerous other drug classes (e.g., certain calcium channel blockers, anticoagulants, and immunosuppressants), co-administration requires therapeutic monitoring and a dose reduction of the interacting medicine.
• Impact on Itraconazole Absorption: The absorption of itraconazole capsules is reduced in conditions of decreased gastric acidity. This applies to patients taking gastric acid secretion suppressors, such as H2-receptor antagonists or proton pump inhibitors (PPIs). In such cases, the regulatory documents specify requirements for staggered administration or the use of an acidic beverage to ensure adequate exposure. Select combinations, such as colchicine and fesoterodine, are contraindicated specifically in patients with impaired renal or hepatic function.

Fungal Enzyme Inhibition and Ergosterol Pathway Blockade

The drug's mechanism initiates at the molecular level by functioning as a highly specific inhibitor of the fungal enzyme lanosterol 14alpha-demethylase (CYPF51). This action effectively blocks a crucial step in the ergosterol biosynthesis pathway. The resulting cessation of ergosterol production and the simultaneous accumulation of toxic 14-methylated sterols initiate the sequence of cellular destabilization.

---

Compromise of Fungal Cell Membrane Structural Integrity

The physiological consequence is a direct result of the molecular blockade. The incorporation of the accumulating defective sterols into the fungal cell's outer layer severely compromises the cell membrane's structural integrity and fluidity. This failure of the essential biological barrier causes leakage of critical internal materials, dysregulating the cell's internal environment and culminating in the loss of fungal cellular viability.

---

Mechanistic Amplification via Active Metabolite

The overall sustained mechanistic action is enhanced by the drug's metabolism. Itraconazole is converted into hydroxy-itraconazole, a metabolite that is equally or more potent than the parent compound. This component continues the inhibition of the 14alpha-demethylase enzyme, resulting in the sustained inhibition of the fungal target.

Official Administration Guidelines for Итразол

Itraconazole is officially administered via the oral route as capsules or an oral solution, with an intravenous (IV) formulation available for systemic treatment where oral intake is not feasible. The correct administration protocol is strictly defined for each formulation to ensure proper systemic delivery of the active substance.

---

Dosing Structure and Administration Context

Property	Administration Principle
Route of Administration	Primarily Oral (Capsules and Solution); IV is an official alternative route.
Timing in Relation to Meals	Capsules must be taken immediately after a full meal to maximize absorption. The Oral Solution is best taken on an empty stomach.
Dosing Schedule Principle	For serious systemic infections, a loading phase of high, often divided, doses (e.g., 200 mg three times daily) is prescribed for the initial three days, followed by a maintenance dose (e.g., 200 mg once or twice daily).
Special Procedural Conditions	The capsule and oral solution are not bioequivalent and should not be used interchangeably. Capsules must be swallowed whole. Antacid or acid-reducing agents should be administered at least 2 hours before or 2 hours after the standard capsule.
Missed-Dose Rule	If a dose is missed, patients should take the next scheduled dose at the usual time and not double the dose to compensate.

---

Contextual Use Protocol

Established guidelines indicate that the bioavailability of the drug is dependent on its formulation and timing relative to food. This Formulation-Dependent Timing is a core principle of correct administration. Treatment duration varies widely, ranging from short courses for conditions like oropharyngeal candidiasis (e.g., 1–2 weeks) to long-term therapy for systemic mycoses (e.g., a minimum of three months). Dose adjustments may be necessary for older adults and patients with impaired hepatic or renal function.

Research Evidence / Overview of Studies for Итразол

Evidence for Use in Systemic Fungal Mycoses

Research exploring the use of Итразол for serious, deep-seated fungal infections, such as Blastomycosis, Histoplasmosis, and Aspergillosis, includes Randomized Controlled Trials (RCTs) and smaller clinical studies. These studies primarily focused on adult patients, including those who were immunocompetent and those who were immunocompromised. Researchers examined outcomes related to clinical cure (resolution of signs and symptoms) and mycological cure (eradication of the fungal pathogen), as well as overall survival and the frequency of relapse. Studies reported measurements of pathogen eradication and observed patterns related to clinical response in some of the studied patients with systemic mycoses. Findings describe group patterns related to how symptoms evolved and the experiences reported by patients over defined time intervals.

Long-term status of patients remains uncertain, as data detailing outcomes beyond one year are limited for certain infections. The evidence quality varies across studies, and some key trials are older, meaning the results apply most directly to the specific populations studied at that time.

Evidence for Antifungal Prophylaxis in High-Risk Patients

Research has explored the use of Итразол for prevention (prophylaxis) of fungal infections in patients considered to be at high risk. The research examined specific adult populations, mainly those with blood cancers who experience periods of profound neutropenia. The studies monitored outcomes such as the incidence of systemic fungal infections and the subsequent need for empirical antifungal therapy. Trials described observed differences in the incidence of proven and suspected systemic fungal infections between the group receiving Итразол and the comparator/placebo group during the short-term observation period.

The results apply only to the specific, critically ill populations studied. Therefore, the research findings apply most directly to the specific immunocompromised populations studied. Follow-up durations were limited, as studies were focused on the short-term high-risk period, and there is limited information for long-term outcomes after that acute phase.

Evidence for Superficial and Keratinized Tissue Infections

The research base for infections affecting superficial areas, such as Onychomycosis and mucosal candidiasis, includes various Randomized Controlled Trials. Researchers monitored outcomes related to complete cure, which combined the clinical appearance with mycological assessments, and how symptoms evolved in the observed populations. The assessment of final cure often required extended follow-up durations, with observation extending up to 40 weeks or more after treatment had concluded. However, the definition of a "complete cure" has varied across studies, making direct comparisons challenging.

Research Gaps and Areas of Uncertainty

For all indications, research has explored the durability of the observed responses, focusing on outcomes measured after the therapy period ends. Evidence for assessing long-term outcomes and sustained absence of infection is not fully established across all indications. The generalizability of findings, particularly from prophylaxis trials focused on narrow, high-risk groups, is an area where further study may be helpful.

Key Studies & References

1. Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials

Common questions about Итразол (FAQ)

Q: What is Итразол used for?

Итразол is indicated for the treatment of certain fungal infections, including those affecting the nails, skin, and mouth. The specific conditions it is used for are determined by regulatory approval in the relevant jurisdiction.

Q: How does Итразол work?

Research suggests that Итразол works by interfering with the synthesis of a key component of the fungal cell membrane, which may disrupt the growth and multiplication of the fungus.

Q: What are the potential side effects of Итразол?

Clinical data indicates that common reported side effects may include gastrointestinal issues such as nausea, abdominal discomfort, and diarrhea. Less common, but more serious, effects concerning liver function have been reported in some studies.

Q: Is Итразол suitable for everyone?

The suitability of Итразол depends on an individual's specific health profile and other medications they may be taking. Contraindications and precautions exist, and suitability should be determined by a qualified healthcare provider.

How to Store and Dispose of Itraconazole (Итразол)

Itraconazole must be stored according to regulatory requirements to ensure product stability. The medicine must be kept out of the sight and reach of children.

---

Storage Conditions

The capsules require storage at Controlled Room Temperature, specifically between 15 C and 25 C (59 F to 77 F). The oral solution must be stored at or below 25 C and must not be frozen. Both formulations must be protected from light and moisture and kept in the original, tightly closed container.

---

Disposal Requirements

Unused or expired Itraconazole should be disposed of through an authorized drug take-back program. If a take-back option is unavailable, the product must be mixed with an unappealing substance, sealed in a container, and discarded in the household trash. It is strictly prohibited to flush the medicine down the toilet or pour it down a sink.